Recent progress with oxazolidinone antibacterial agents

Bibliography

• SWARTZ MN: Hospital-acquired infections: diseases with increasingly limited therapies. Proc. Nati Acad. Sci. USA (1994) 91 :2420–2427.
   PubMed Web of Science ®Google Scholar
• TOMASZ A: Multiple-antibiotic-resistant pathogenic bacteria. N Engl. J. Med. (1994) 330:1247–1251.
   PubMed Web of Science ®Google Scholar
• FEKETE T: Bacterial genetics, antibiotic usage and public policy: the crucial interplay in emerging resistance. Perspect. Biol. Med. (1995) 38:363–382.
   PubMedGoogle Scholar
• BRUMFITT W, HAMILTON-MILLER JMT: The challenge of methicillin-resistant Staphylococcus aureus. Drugs Exp. Clin. Res. (1994) 20:215–224.
   PubMedGoogle Scholar
• LOW DE, WILLEY BM, MCGEER AJ: Multidrug-resistant enterococci: a threat to the surgical patient. Am]. Surg. (1995) 5A(Suppl.):8S–12S.
   Google Scholar
• SPERA RV, FARBER BF: Multidrug-resistant Entero-coccus faecium: an untreatable nosocomial pathogen. Drugs (1994) 48:678–688.
   PubMed Web of Science ®Google Scholar
• APPELBAUM PC: Antimicrobial resistance in Strepto-coccus pneumoniae. Clin. Infect. Dis. (1992) 15:77–83.
   PubMed Web of Science ®Google Scholar
• HIRAMATSU K, HANAKI H, INO T, YABUTA K, OGURI T, TENOVER FC: Methicillin -resistantStaphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. (1997) 40:135–136.
   PubMed Web of Science ®Google Scholar
• SMITH TL, PEARSON ML, WILCOX KR etal.: Emergence of vancomycin resistance in Staphylococcus aureus. N Eng. J. Med. (1999) 340:493–501.
   Google Scholar
• SIERADZKI K, ROBERTS RB, HABER SW, THOMASZ A: The development of vancomycin resistance in a patient with methicillin -resistant staphylococcus aureus infection. N Engl. J. Med. (1999) 340:517–523.
   PubMed Web of Science ®Google Scholar
• WALDVOGEL FA: New resistance in resistant Staphylo-coccus aureus. N Eng. J. Med. (1999) 340:556–557.
   PubMed Web of Science ®Google Scholar
• KAATZ GW, SEO SM: In vitro activities of oxazolidinone compounds U-100592 and U-100766 against Staphylo-coccus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. (1996):799–801.
   PubMedGoogle Scholar
• BRICKNER SJ, HUTCHINSON DK, BARBACHYN MR et al.: and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant-positive bacterial infections. J Med. Chem. (1996) 39:673–679.
   PubMed Web of Science ®Google Scholar
• BRICKNER SJ: Ox azolidin on e antibacterial agents. Cur.Pharm. Design (1996) 2:175–194.
   Web of Science ®Google Scholar
• SHINABARGER D: Mechanism of action of theoxazolidinone antibacterial agents. Exp. Opin. Invest. Drugs (1999) 8:1195–1202.
   PubMedGoogle Scholar
• •Recent review of oxazolidinone mechanism of action.
   Google Scholar
• UN AH, MURRAY RW, VIDMAR TJ, MAROTTI KR: The oxazolidinone eperezolid binds to the 50s ribosomal subunit and competes with binding of chloram-phenicol and lincomycin. Antimicrob. Agents Chemother. (1997) 41:2127–2131.
   PubMed Web of Science ®Google Scholar
• SHINABARGER DL, MAROTTI KR, MURRAY RW et al: Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. (1997) 41:2132–2136.
   PubMed Web of Science ®Google Scholar
• MATASSOVA NB, RODNINA MV, ENDERMANN R et al:Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RATA (1999) 5:939–946.
   Google Scholar
• •Mechanism of action study.
   Google Scholar
• ZURENKO GE, YAGI BH, SCHAADT RD et al: In vitroactivities of U-100592 and U-100766, novel oxazolidi-none antimicrobial agents. Antimicrob. Agents Chemother. (1996):839–845.
   PubMedGoogle Scholar
• SWANEY SM, SHINABARGER DL, SCHAADT RD, BOCK JH,SLIGHTON JL, ZURENKO GE: Oxazolidinone resistance is associated with a mutation in the peptidyl transfe-rase region of 23S rRNA. 38th ICAAC. San Diego, California, USA (1998) Abstract C–104.
   Google Scholar
• JONES RN, PFALLER MA, ERWIN ME, BEACH ML: Antimi-crobial activity of linezolid (PNU-100766) tested against 7,599 recent clinical isolates from over 50 medical center laboratories. 39th ICAAC. San Francisco, California, USA (1999) Abstract E–1263.
   Google Scholar
• WILKS NE: Safety and tolerance of linezolid in Phase II trials. 39th ICAAC. San Francisco, California, USA (1999) Abstract A–1763.
   Google Scholar
• WIENKERS LC, WYNALDA MA, FEENSTRA KU, GAO P, SLATTER JG: In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabo-lite, PNU-142586. 39th ICAAC. San Francisco, California, USA (1999) Abstract A–11.
   Google Scholar
• BIRMINGHAM MC, ZIMMER GS, HAFKIN B et al.: Outcomes with linezolid (LZD) from an ongoing compassionate use (CU) trial of patients (Pts) with significant, resistant, Gram-positive infections. 39th ICAAC. San Francisco, California, USA (1999) Abstract M–1098.
   Google Scholar
• ZURENKO GE, TODD WM, HAFKIN B et al.: Developmentof linezolid-resistant enterococcus faecium in two compassionate use program patients treated with linezolid. 39th ICAAC, San Francisco, California, USA (1999) Abstract C1–848.
   Google Scholar
• POEL TJ, THOMAS RC, BARBACHYN MR et al: Synthesis and biological evaluation of tetrahydro4(2H)-thiopyr-anyl phenyloxazolidinone sulfoxides and sulfones as novel antibacterial agents. 39th ICAAC. San Francisco, California, USA (1999) Abstract F–568.
   Google Scholar
• GENIN MJ, ALLWINE DA, ANDERSON DJ et al.: Substituent effects on the antibacterial activity of nitrogen-carbon linked azolylphenyl oxazolidinones with expanded activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis. J. Med. Chem. (2000) 43:953–970.
   PubMed Web of Science ®Google Scholar
• •Extensive SAR study. Analogues have Gram-negative activity.
   Google Scholar
• GENIN MJ, HUTCHINSON DK, ALLWINE DA et al.: -carbon-linked (azolylphenyl)ox azo lidi-nones with potent antibacterial activity against the fastidious Gram-negative organisms haemophilus influenzae and moraxella catarrhalis. J. Med. Chem. (1998) 41:5144–5147.
   PubMedGoogle Scholar
• •SAR study. Analogues have Gram-negative activity.
   Google Scholar
• GAD WOOD RC, THOMASCO LM, WEAVER EA, ZURENKOGE, FORD CW: Synthesis and antibacterial activity of azolylphenyloxazolidinones having 1,3,4-thiadiazoly1 C-rings. 39th ICAAC. San Francisco, California, USA (1999) Abstract F–571.
   Google Scholar
• GENIN MJ, ALLWINE DA, ANDERSON DJ et al.: Carbon-carbon linked 5-membered heteroarylphenyl oxazolidinones with broad spectrum antibacterial activity. 39th ICAAC. San Francisco, California, USA (1999) Abstract F–570.
   Google Scholar
• GENIN MJ, ALLWINE DA, BARBACHYN MR et al.: Synthesis and antibacterial evaluation of new carbon-carbon linked pyrazolylphenyloxazolidinones. The quest for Gram negative activity. 17th International Congress of Heterocyclic Chemistry. Vienna Austria, 1–6 August, 1999 Abstract 269.
   Google Scholar
• HAEBICH D, BARTEL S, ENDERMANN R et al.: Synthesis and antibacterial activity of novel heteroaryl oxazolidinones: II. benzoxazinone- and benzthiazinone-oxazolidinones. 39th ICAAC. San Francisco, California, USA (1999) Abstract F–566.
   Google Scholar
• BARTEL S, ENDERMANN R, GUARNIERI W et al.: Synthesis and antibacterial activity of novel heteroaryl azolidin ones:I. pyrazinoin dole- andoxazinoindole-oxazolidinones. 39th ICAAC. San Francisco, California, USA (1999) Abstract F–565.
   Google Scholar
• ELIPOULOS GM, WENNERSTEN CB, GOLD HS, MOELLERING RC: In vitro activities of new oxazolidi-none antimicrobial agents against enterococci.Antimi-crob. Agents Chemother. (1996) 40 (7) :1745–1747.
   Google Scholar
• BARBACHYN MR, CLEEK GJ, DOLAK LA et al.: Ox azolidi-none bioisosteres: studies leading to the identification of phenyloxazolidinones as novel and potent antibac-terial agents. 39th ICAAC. San Francisco, California, USA (1999) Abstract F–572.
   Google Scholar
• GREGORY WA, BRITTELLI DR, WANG CL et al: Antibacte-rials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidinones. 1. The 'B' group. J. Med. Chem. (1989) 32:1673.
   Google Scholar
• BUYSSE JM, DEMYAN WF, DUNYAK DS, STAPERT D, HAMEL JC, FORD CW: Mutation of the acrAB antibiotic efflux pump in Escherichia coli confers susceptibility to oxazolidinone antibiotics. 36th ICAAC. San Francisco, California, USA (1996) Abstract 62.
   Google Scholar
• FORD CW, HAMEL J, STAPERT D et al: Oxazolidinones: anew class of antimicrobials. Infect. Med. (1999):435–445.
   Google Scholar
• AstraZeneca seeks cautious expansion in CNS/infection. Scrip (17 December, 1999) No. 2499:13.
   Google Scholar